Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2003
02/05/2003EP1281756A1 Regulator of calcineurin
02/05/2003EP1281715A1 Process for the preparation of ribavirin
02/05/2003EP1281711A1 Interstrand crosslinking agents for dna and compounds therefor
02/05/2003EP1281709A1 Novel heterocyclic compounds with anti-inflammatory activity
02/05/2003EP1281707A1 Process for the preparation of 5-subtituted isobenzofurans
02/05/2003EP1281702A2 Calcium receptor active molecules
02/05/2003EP1281400A2 Pharmaceutical compositions containing ascomycin derivatives
02/05/2003EP1281399A2 Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
02/05/2003EP1281398A1 Dermal compositions containing coenzyme q as the active ingredient
02/05/2003EP1281397A1 Orally administered controlled drug delivery system providing temporal and spatial control
02/05/2003EP1281396A2 Skin vitalizing composition for external use anti-aging preparation
02/05/2003EP1281324A2 Health food products
02/05/2003EP1281083A1 Methods for detecting inflammation and inflammatory conditions
02/05/2003EP1280924A2 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
02/05/2003EP1280921A1 Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy
02/05/2003EP1280908A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
02/05/2003EP1280907A2 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods
02/05/2003EP1280906A2 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
02/05/2003EP1280905A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene carboxy terminal peptides
02/05/2003EP1280898A1 Modified es cells and es cell-specific gene
02/05/2003EP1280897A2 Regulation of nf-at interacting protein nip 45 variant
02/05/2003EP1280891A1 Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
02/05/2003EP1280813A1 Anti-viral pyrimidine nucleoside analogues
02/05/2003EP1280812A1 Cyclipostins, a method for their production and the use of the same
02/05/2003EP1280809A1 Antitumoral ecteinascidin derivatives
02/05/2003EP1280806A1 THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
02/05/2003EP1280805A1 Novel imidazotriazinones and the use thereof
02/05/2003EP1280803A1 Crystalline form ii of cabergoline
02/05/2003EP1280802A1 Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation
02/05/2003EP1280801A2 Hydantoin-containing glucokinase activators
02/05/2003EP1280800A1 N-sulfonyl hydroxamic acid derivatives as inhibitors of cd 23
02/05/2003EP1280799A1 Ortho-substituted anthranilic acid amides and their use as medicaments
02/05/2003EP1280798A1 Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
02/05/2003EP1280797A1 Inhibitors of dipeptidyl peptidase iv
02/05/2003EP1280796A1 Pyrimidinyl methyl indole derivatives with antibacterial activity
02/05/2003EP1280795A2 N-substituted carbamoyloxyalkyl-azolium derivatives
02/05/2003EP1280793A2 Cyclic amidine compounds and their use as alpha4beta2 nicotinic acetylcholine receptor ligands
02/05/2003EP1280789A1 Cdk inhibitors having 3-hydroxychromen-4-one structure
02/05/2003EP1280788A1 Method for the production of l-ascorbic acid by lactonisation of 2-keto-l-gulonic acid or 2-keto-l-gulonate esters
02/05/2003EP1280785A1 Phenylsulphonylpiperazinyl derivatives as 5-ht receptor ligands
02/05/2003EP1280781A1 5-ht 7 receptor antagonists
02/05/2003EP1280779A1 New polycyclic indanylimidazoles with alpha2 adrenergic activity
02/05/2003EP1280777A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
02/05/2003EP1280776A1 Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
02/05/2003EP1280774A1 Substituted indoles as parp inhibitors
02/05/2003EP1280772A2 Triaryl cation antibiotics from environmental dna
02/05/2003EP1280766A1 Biocidal polymers based on guanidine salts
02/05/2003EP1280764A2 Inhibitors of histone deacetylase
02/05/2003EP1280759A1 Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
02/05/2003EP1280757A2 New gamma selective retinoids
02/05/2003EP1280604A1 Media milling
02/05/2003EP1280572A1 Delivery devices for treatment of vascular disease
02/05/2003EP1280571A1 Delivery devices for treatment of vascular disease
02/05/2003EP1280570A2 Delivery devices for treatment of vascular disease
02/05/2003EP1280569A1 Delivery systems for treatment of vascular disease
02/05/2003EP1280568A1 Delivery devices for treatment of vascular disease
02/05/2003EP1280566A2 Growth factor modified protein matrices for tissue engineering
02/05/2003EP1280559A2 Acylated cyclodextrin guest inclusion complexes
02/05/2003EP1280557A1 Method for the preparation of polymeric micelle via phase separation of block copolymer
02/05/2003EP1280556A1 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
02/05/2003EP1280555A2 Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist
02/05/2003EP1280554A2 A pharmaceutical composition and method of treatment of diseases of cognitive dysfuntion in a mammal
02/05/2003EP1280547A2 Mast cell regulation
02/05/2003EP1280546A1 Method and composition for the treatment of angiogenesis
02/05/2003EP1280543A2 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom
02/05/2003EP1280537A2 Compositions of non-ionic block copolymers to treat autoimmune, proliferative, and inflammatory diseases and methods of use thereof
02/05/2003EP1280536A2 Method for treating retinal degeneration with purinergic receptor agonists
02/05/2003EP1280535A1 Processes for preparing clarithromycin polymorphs
02/05/2003EP1280533A2 Aldosterone antagonist composition for release during aldosterone acrophase
02/05/2003EP1280532A1 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
02/05/2003EP1280531A1 Local anesthetic methods and kits
02/05/2003EP1280530A1 Treatment of fibromyalgia and chronic fatigue syndrome
02/05/2003EP1280529A2 Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
02/05/2003EP1280528A2 R-eliprodil for treating glaucoma
02/05/2003EP1280527A2 Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
02/05/2003EP1280526A1 Composition for the prevention and/or treatment, in newborn babies, of the effects of complications during childbirth
02/05/2003EP1280525A2 Methods and compositions for modulating alpha adrenergic receptor activity
02/05/2003EP1280524A2 Methods and compositions for modulating alpha adrenergic receptor activity
02/05/2003EP1280523A2 Use of benzamide derivatives for the treatment of high ocular tension and glaucoma
02/05/2003EP1280522A2 Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
02/05/2003EP1280518A2 Liposome drug delivery
02/05/2003EP1280516A1 Method for transdermal or intradermal delivery of molecules
02/05/2003EP1280515A2 Pharmaceutical compositions comprising cannabis
02/05/2003EP1280514A1 Evaporative coolant comprising hydrofluorocarbons and /or hydrochlorofluorocarbons
02/05/2003EP1280512A2 Delivery systems for treatment of vascular disease
02/05/2003EP1280500A2 Synergistic antiplaque/antigingivitis oral composition
02/05/2003EP1280496A2 Cosmetic agents containing 2-furanone derivatives
02/05/2003EP1280495A2 3-methoxybenzyl thiourea derivatives and improved lipid compositions containing same
02/05/2003EP1280486A1 Minimizing adverse experience associated with oxybutynin therapy
02/05/2003EP1280485A1 Improved transdermal drug patch
02/05/2003EP1280420A1 Natural vegetable oil concentrated in unsaponifiable matters as food ingredient
02/05/2003EP1280416A1 Pet food composition for reducing inflammatory response in cats
02/05/2003EP1223918B1 Pharmaceutical compositions comprising a hmg coa reductase inhibitor
02/05/2003EP1200101A4 Methods for transdifferentiation of body tissues
02/05/2003EP1194145B1 Stable xylometazoline and oxymetazoline solution
02/05/2003EP1117653B1 Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
02/05/2003EP1104294A4 Compositions and methods of treating abnormal cell proliferation
02/05/2003EP1086078B1 Neuropeptide y5 receptor antagonists
02/05/2003EP1064009B9 Utilization of extracts from iris plants, cimicifuga racemosa and tectorigenin as an estrogen-like organ-selective medicament without uterotropic effects
02/05/2003EP1051174B1 Gastroprotected omerprazole microgranules, method for obtaining same and pharmaceutical preparations
1 ... 5571 5572 5573 5574 5575 5576 5577 5578 5579 5580 5581 5582 5583 5584 5585 5586 5587 5588 5589 5590 5591 ... 7860